Novartis: breast cancer patients benefited from Kisqali
(CercleFinance.com) - Nearly 60% of advanced breast cancer patients enrolled in three clinical trials with visceral metastases benefited from treatment with Novartis' Kisqali, the Swiss drugmaker said on Monday.
In a first phase III study, Kisqali plus endocrine therapy extended median progression-free survival by 11.5 months in patients with visceral metastases (24.9 months vs. 13.4 months), the company said.
In a second trial, Kisqali plus endocrine therapy improved median progression-free survival by 13.4 months (23.8 months vs 10.4 months), it said.
However, in the third trial, median progression-free survival for patients with visceral metastases still has not been reached its primary target compared to patients receiving endocrine therapy alone, Novartis said.
The group nevertheless thinks that these results support the use of Kisqali combination therapy as a standard of care for advanced breast cancer in patients with difficult-to-treat visceral disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In a first phase III study, Kisqali plus endocrine therapy extended median progression-free survival by 11.5 months in patients with visceral metastases (24.9 months vs. 13.4 months), the company said.
In a second trial, Kisqali plus endocrine therapy improved median progression-free survival by 13.4 months (23.8 months vs 10.4 months), it said.
However, in the third trial, median progression-free survival for patients with visceral metastases still has not been reached its primary target compared to patients receiving endocrine therapy alone, Novartis said.
The group nevertheless thinks that these results support the use of Kisqali combination therapy as a standard of care for advanced breast cancer in patients with difficult-to-treat visceral disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.